Yuping Bai
Overview
Explore the profile of Yuping Bai including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
187
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhu L, Bai Y, Zhang L, Si W, Wang A, Weng C, et al.
Foods
. 2023 Feb;
12(4).
PMID: 36832787
Stable and sustainable food production is an important guarantee for national security and social stability. The uneven distribution of cultivated land and water resources will threaten national food security. In...
12.
Yu Y, Yu R, Wang N, Bai Y, Shi Q, Maswikiti E, et al.
Front Pharmacol
. 2023 Feb;
14:1063775.
PMID: 36778024
The immune checkpoint inhibitor (ICI) has been approved as the first-line therapy for metastatic gastric cancer in China. The treatment response of immune checkpoint inhibitor is highly dependent on the...
13.
Qi W, Xi D, Bai Y, Liu L, Ma Y, Yin Z, et al.
Front Pharmacol
. 2023 Jan;
14:1026135.
PMID: 36713848
Lung cancer is a major public health issue and an enormous burden on society in China. Most lung cancers occur in elderly patients with non-small cell lung cancer (NSCLC), and...
14.
Bai Y, He T, Zhang L, Liu Q, Yang J, Zhao Z, et al.
BMJ Open
. 2023 Jan;
12(9):e060659.
PMID: 36691128
Objectives: We aimed to comprehensively evaluate the relationship between forkhead box P3 (FOXP3) regulatory T cell (Treg) expression and diffuse large B-cell lymphoma (DLBCL) prognosis and to explore the sources...
15.
Yang J, Liu Q, Bai Y, Zhao H, He T, Zhao Z, et al.
Front Oncol
. 2023 Jan;
12:1025855.
PMID: 36686727
Objective: Whether lymph node micrometastasis (LNM) increases the risk in esophageal cancer patients remains controversial. We conducted a systematic review and meta-analysis to explore the prognosis value of LNM in...
16.
Yu Y, Bai Y, Zheng P, Wang N, Deng X, Ma H, et al.
BMC Cancer
. 2022 Nov;
22(1):1241.
PMID: 36451109
Background: Immune checkpoint inhibitors (ICIs) represent an approved treatment for various cancers; however, only a small proportion of the population is responsive to such treatment. We aimed to develop and...
17.
Difference in Intestinal Flora and Characteristics of Plasma Metabonomics in Pneumoconiosis Patients
Li Y, Xiao K, Xiao S, Wang M, Pei S, Liu H, et al.
Metabolites
. 2022 Oct;
12(10).
PMID: 36295819
From the two perspectives of intestinal flora and plasma metabolomics, the mechanism of occurrence and development of pneumoconiosis was explored to provide a new target for the prevention and treatment...
18.
Liu L, Bai Y, Xiang L, Qi W, Gao L, Li X, et al.
Clin Transl Oncol
. 2022 Sep;
24(12):2330-2341.
PMID: 36103048
Chemotherapeutic drugs play an important role in the treatment of cancer, but the individual differences of patients' sensitivity to chemotherapeutic drugs and the drug resistance of chemotherapeutic drugs have always...
19.
Yu H, Bai Y, Xie X, Feng Y, Yang Y, Zhu Q
BMJ Open
. 2022 Jun;
12(6):e052294.
PMID: 35649603
Objectives: Response Evaluation Criteria in Solid Tumours version 1.1 (RECIST 1.1) and modified RECIST (mRECIST) are commonly used to assess tumour response. Which one is better to evaluate efficacy after...
20.
Qi W, Bai Y, Wang Y, Liu L, Zhang Y, Yu Y, et al.
APMIS
. 2022 Mar;
130(7):371-382.
PMID: 35255180
Accurate assessment of the tumour immune microenvironment promotes individualized immunotherapy regimens and screens dominant populations suitable for immunotherapy. Therefore, potential molecular markers were investigated to make an overall assessment of...